On a mission improving cancer care for millions of lives
We are a Danish biotech company developing a more gentle and efficient cancer care. Our team are the pioneers behind the novel uPAR Theranostics technology. A technology that minimizes irradiation of healthy tissue by combining the targeted uTREAT® radiation therapy, with precise uTRACE® diagnostics. Several investigator-initiated phase II clinical trials have been completed or are currently undertaken.
Latest press releases
The exercise price for warrants of series TO2 has been set to DKK 11.50 per new share
Curasight to present at HC Andersen Capital, BioStock Life Science Summit 2024, and Økonomisk Ugebrev Investor Conference
Curasight announces international patent application for uTREAT® to broaden IP protection
How our technology works
Curasight was listed on Spotlight Stock Market in October 2020. See the information video from the initial public explaining how the technology works.
Be part of funding the cancer treatment of tomorrow
With aging populations, increased number of cancers, wider use of nuclear medicine and introductions of new radiopharmaceuticals around the world as growth factors, the market is expected to grow rapidly. Based on promising results, Curasight’s Board and management projects that their technology could become game-changing in the management of cancer patients.
